https://i2obio.com i2O Therapeutics, a developer of oral biologic products based on its proprietary ionic liquid platform, today announced a collaboration and option agreement with Janssen Biotech, Inc., for Janssen Research & Development to evaluate the use of ionic liquid technology for the oral delivery of macromolecules. https://www.biospace.com/i2o-therapeutics-announces-research-collaboration-and-option-agreement-with-janssen-to-investigate-the-oral-delivery-of-macromolecules